PLAT antibody, PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope Antibody, Mouse IgG1 Monoclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope Antibody, Mouse IgG1 Monoclonal Antibody

Catalog Number: 20-321-175244

Buy PLAT antibody -

Size:

Related Product Names:

- PLAT antibody; PLAT; PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope
- MONOCLONAL ANTIBODY TO RAT PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope; EC 3.4.21.68; tPA; t-PA; t-plasminogen activator; Alteplase; Reteplase; Plasminogen activator; Tissue-type plasminogen activator

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: PLAT	Gene Name Synonym: N/A
Gi #: 339834	NCBI Acc #: AAB59510.1	Swiss Prot Acc #: P00750
Length (aa): 562	Mol. Weight (Da): 62917	Chrom Location: N/A

Clone: MA-124K1

Applications: The monoclonal antibody MA-124K1 can be used for immuno assays. Furthermore MA-124K1 is useful for inhibition of biological activity.

Source/Host: Mouse IgG1

Clonality: Monoclonal

Crossreactivity: Rat

Format: 1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS. containing 0.1% bovine serum albumin.

Storage: Product should be stored at 4 degree C

Stability: Stable for 1 year

Shipping: Products may be shipped on ice pack or dry ice.

TESTING: (secondary reagents and protocols )

Not Available

PLAT ANTIBODY TARGET DESCRIPTION:

Synonym Names for PLAT antibody: PLAT; MONOCLONAL ANTIBODY TO RAT PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope; EC 3.4.21.68; tPA; t-PA; t-plasminogen activator; Alteplase; Reteplase; Plasminogen activator; Tissue-type plasminogen activator

Plasminogen activator inhibitor type-1 (PAI-1). a member of the serine protease inhibitor (serpin) superfamily is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable. inactive complex. Although PAI-1 is synthesized as an active molecule. it converts spontaneously to an inactive. latent form that can be partially reactivated by denaturing agents. In addition. a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified. The epitope of monoclonal antibody MA-124K1 is a conformational epitope close to the reactive-site loop. Glu220 and Glu212 constitute the main molecular determinants of the epitope for MA-124K1. The monoclonal antibody MA-124K1 inhibits PAI-1 activity and simultaneously increases the binding of inactive PAI-1 to vitronectin. The effect of the antibody involves an allosteric modulation of the vitronectin binding site. The antibody cross reacts with mouse PAI-1.

Function: Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.

Catalytic Activity: Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.

Subunit: Heterodimer of chain A and chain B held by a disulfide bond. Binds to fibrin with high affinity. This interaction leads to an increase in the catalytic efficiency of the enzyme between 100-fold and 1000-fold, due to an increase in affinity for plasminogen. Similarly, binding to heparin increases the activation of plasminogen. Binds to annexin A2, cytokeratin-8, fibronectin and laminin. Binds to mannose receptor and the low-density lipoprotein receptor-related protein (LRP1); these proteins are involved in TPA clearance. Yet unidentified interactions on endothelial cells and vascular smooth muscle cells (VSMC) lead to a 100-fold stimulation of plasminogen activation. In addition, binding to VSMC reduces TPA inhibition by PAI-1 by 30-fold. Binds LRP1B; binding is followed by internalization and degradation.

Subcellular Location: Secreted, extracellular space.

Tissue Specificity: Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.

Domain: Both FN1 and one of the kringle domains are required for binding to fibrin.

Domain: Both FN1 and EGF-like domains are important for binding to LRP1.

Domain: The FN1 domain mediates binding to annexin A2.

Domain: The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.

Ptm: The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.

Ptm: Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.

Ptm: N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.

Ptm: Characterization of O-linked glycan was studied in Bowes melanoma cell line.

Disease: Increased activity of TPA causes hyperfibrinolysis, with excessive bleeding as a consequence.

Disease: Defective release of TPA causes hypofibrinolysis, leading to thrombosis or embolism.

Pharmaceutical: Available under the names Activase (Genentech) and Retavase (Centocor and Roche) [Retavase is a fragment of TPA that contains kringle 2 and the protease domain; it was also known as BM 06.022]. Used in Acute Myocardial Infarction (AMI), in Acute Ischemic Stroke (AIS) and Pulmonary Embolism (PE) to initiate fibrinolysis.

Similarity: Belongs to the peptidase S1 family [view classification].

Similarity: Contains 1 EGF-like domain.

Similarity: Contains 1 fibronectin type-I domain.

Similarity: Contains 2 kringle domains.

Similarity: Contains 1 peptidase S1 domain [view classification].

PLASMINOGEN ACTIVATOR TYPE 1 (PAI-1) . E212/E220 epitope reacts with rat.

OMIM: 173370; gene+phenotype. [NCBI / EBI]

Products similar to PLAT antibody:

IgG

PDGFR alpha (ready-to-use), IgG

CD31 [JC/70A], IgG

Integrin alpha 2b [MEM-06], IgG

Integrin beta 3 [F11] (Biotin), IgG

Integrin alpha 2b [HIP2], IgG

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

BACKGROUND REFERENCES for PLAT ANTIBODY:

Background references for antibody target are not specific to GenWay products

[1] Pennica,D., Holmes,W.E., Kohr,W.J., Harkins,R.N., Vehar,G.A., Ward,C.A., Bennett,W.F., Yelverton,E., Seeburg,P.H., Heyneker,H.L.,, et al.
     Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
[2] Pennica D., Holmes W.E., Kohr W.J., Harkins R.N., Vehar G.A., Ward C.A., Bennett W.F., Yelverton E., Seeburg P.H., Heyneker H.L., et al.
     Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.
[3] Ny T., Elgh F., Lund B.
     The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains.
[4] Harris T.J., Patel T., Marston F.A., Little S., Emtage J.S., Opdenakker G., Volckaert G., Rombauts W., Billiau A., Somer P., et al.
     Cloning of cDNA coding for human tissue-type plasminogen activator and its expression in Escherichia coli.
[5] Friezner Degen S.J., Rajput B., Reich E.
     The human tissue plasminogen activator gene.
[6] Reddy V.B., Garramone A.J., Sasak H., Wei C.-M., Watkins P., Galli J., Hsiung N.
     Expression of human uterine tissue-type plasminogen activator in mouse cells using BPV vectors.
[7] Sasaki H., Saito Y., Hayashi M., Otsuka K., Niwa M.
     Nucleotide sequence of the tissue-type plasminogen activator cDNA from human fetal lung cells.
[8] Siebert P.D., Fong K.
     Variant tissue-type plasminogen activator (PLAT) cDNA obtained from human endothelial cells.
[9] Liu Y., Xu L., Zeng Y., He X.
     cDNA of tissue plasminogen activator.
[10] Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., et al.
     Cloning of human full-length CDSs in BD Creator(TM) system donor vector.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: PLAT antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of PLAT antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about PLAT antibody, all related information, articles, resources about PLAT antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved